ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,686.12
0.61%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. AMEX
  6. Matinas Biopharma Holdings Inc (MTNB)

  7. Matinas Biopharma Holdings Inc (MTNB) 뉴스

MTNB

Matinas Biopharma (MTNB)

Matinas Biopharma Holdings Inc
일자:
정렬 기준:
 검색 관련기사 보기:AMEX:MTNB
일자시간출처헤드라인심볼기업
2024/05/1620:00GlobeNewswire Inc.New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024AMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/1005:06Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/1005:05GlobeNewswire Inc.Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/1005:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/0721:00GlobeNewswire Inc.Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingAMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/0220:00GlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024AMEX:MTNBMatinas Biopharma Holdings Inc
2024/04/3021:00GlobeNewswire Inc.In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyAMEX:MTNBMatinas Biopharma Holdings Inc
2024/04/0321:30GlobeNewswire Inc.Matinas BioPharma Prices $10 Million Registered Direct OfferingAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2805:05GlobeNewswire Inc.Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2521:00GlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2222:15GlobeNewswire Inc.Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2219:30GlobeNewswire Inc.Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2622:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2622:00GlobeNewswire Inc.Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2021:35Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2021:30GlobeNewswire Inc.Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisAMEX:MTNBMatinas Biopharma Holdings Inc
2024/01/0921:30Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/01/0321:00GlobeNewswire Inc.Matinas BioPharma to Present at Biotech Showcase 2024AMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2721:40Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2721:30GlobeNewswire Inc.Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2121:40Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2121:30GlobeNewswire Inc.Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
 검색 관련기사 보기:AMEX:MTNB

최근 히스토리

NASDAQ
TYDEV
Crptyde
BOV
PETR4Q
PETROBRAS PN
TG
KSB
KSB
COIN
BBTCETH
Binance Wrapped BTC
USOTC
GORLF
G11 Resources (PK)
AMEX
ROM
ProShares Ultra Technology
ASX
ICGNG
Inca Minerals
ASX
URFHC
US Masters Residential P...
BOV
ALLD3R
Allied Tecnologia ON
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유